Pharma BD Deal Intelligence
BMS paid $800M upfront plus up to $7.6B in milestones for BL-B01D1, a first-in-class EGFRxHER3 bispecific ADC from Chinese biotech SystImmune. One of the largest single-asset licensing deals ever, reflecting the ADC boom and Big Pharma's appetite for Chinese-originated molecules.
Bristol Myers Squibb announced an $800 million upfront agreement with SystImmune for BL-B01D1, continuing the pharmaceutical industry momentum in antibody-drug…
Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China's SystImmune in a deal that could swell to $8.4 billion.
Bristol Myers Squibb and SystImmune entered a global ADC collaboration worth potentially up to $8.4 billion for the development and commercialization of…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Bristol-Myers Squibb entered an exclusive global license and collaboration agreement with SystImmune for BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. BMS paid $800 million upfront with up to $500 million in contingent near-term payments and an additional $7.1 billion in development, regulatory, and sales milestones. SystImmune retained rights in Mainland China; BMS gained ex-China development and commercialization rights.
Iza-bren (BL-B01D1; izalontamab brengitecan) is a Phase II/III EGFRxHER3 bispecific ADC under BMS/SystImmune development for metastatic breast cancer (HER2-low, TNBC), entering a market defined by HER2-targeted ADCs and TROP2-targeted ADCs. HER2-targeted ADCs (adjacent MOA class): trastuzumab deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca) is FDA-approved in HER2-positive and HER2-low metastatic breast cancer per DESTINY-Breast03/04/06 — 2023 global sales ~$2.6B (AZ 2023 full-year results); trastuzumab emtansine (Kadcyla, Roche) in adjuvant/2L HER2-positive; disitamab vedotin (RC48, RemeGen) approved in China. TROP2-targeted ADCs (competing in TNBC/HR+ HER2-low): sacituzumab govitecan (Trodelvy, Gilead) FDA-approved in TNBC and HR+/HER2- metastatic breast; datopotamab deruxtecan (Datroway, AZ/Daiichi) FDA-approved Jan 2025 for HR+/HER2- breast. Anti-HER3 (direct half of Iza-bren mechanism): patritumab deruxtecan (HER3-DXd, Daiichi/Merck) — Phase III in HR+/HER2- breast and EGFR-mutant NSCLC. EGFR-targeted ADCs in breast: limited precedent. HER2-targeted TKIs (different MOA): tucatinib (Tukysa, Pfizer), lapatinib (Tykerb, generic), neratinib (Nerlynx, Puma). For a commercial lead, Iza-bren's breast-cancer threat is bounded by Enhertu's incumbency in HER2-low and the TROP2 wave; the EGFRxHER3 mechanism is unique and will require dedicated biomarker positioning.
Metastatic urothelial carcinoma (mUC) is Iza-bren's most contested arena given overlapping EGFR/HER expression and an entrenched ADC class. Nectin-4 ADCs: enfortumab vedotin (Padcev, Astellas/Pfizer) is the frontline standard in combination with pembrolizumab following EV-302 (FDA-approved December 2023), generating ~$1.0B in 2023. HER2 ADCs: trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) received tumor-agnostic accelerated approval April 2024 for HER2-positive solid tumors including mUC; disitamab vedotin (Aidixi, RemeGen/Seagen) is approved in China for HER2-expressing mUC. FGFR TKIs: erdafitinib (Balversa, J&J) is approved for FGFR2/3-altered mUC post-platinum. Anti-PD-1/PD-L1: pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS), and avelumab (Bavencio, Merck KGaA/Pfizer) serve maintenance and second-line roles. Platinum chemotherapy (cisplatin/carboplatin+gemcitabine) remains the chemo backbone. Iza-bren's EGFRxHER3 bispecific ADC profile differentiates on dual-receptor engagement, but the commercial threat is severe: Padcev+pembro has redefined 1L and is expanding to earlier lines (EV-304, EV-303), and Enhertu's tumor-agnostic label preempts HER-driven ADC whitespace. BMS will need to position Iza-bren in post-Padcev or Padcev-ineligible populations.
Metastatic urothelial carcinoma (mUC) is Iza-bren's most contested arena given overlapping EGFR/HER expression and an entrenched ADC class. Nectin-4 ADCs: enfortumab vedotin (Padcev, Astellas/Pfizer) is the frontline standard in combination with pembrolizumab following EV-302 (FDA-approved December 2023), generating ~$1.0B in 2023. HER2 ADCs: trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) received tumor-agnostic accelerated approval April 2024 for HER2-positive solid tumors including mUC; disitamab vedotin (Aidixi, RemeGen/Seagen) is approved in China for HER2-expressing mUC. FGFR TKIs: erdafitinib (Balversa, J&J) is approved for FGFR2/3-altered mUC post-platinum. Anti-PD-1/PD-L1: pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS), and avelumab (Bavencio, Merck KGaA/Pfizer) serve maintenance and second-line roles. Platinum chemotherapy (cisplatin/carboplatin+gemcitabine) remains the chemo backbone. Iza-bren's EGFRxHER3 bispecific ADC profile differentiates on dual-receptor engagement, but the commercial threat is severe: Padcev+pembro has redefined 1L and is expanding to earlier lines (EV-304, EV-303), and Enhertu's tumor-agnostic label preempts HER-driven ADC whitespace. BMS will need to position Iza-bren in post-Padcev or Padcev-ineligible populations.
Iza-bren (BL-B01D1) is a Phase II/III EGFRxHER3 bispecific antibody-drug conjugate under BMS/SystImmune development; in metastatic breast cancer it faces a dense, fast-moving ADC and targeted-therapy landscape. HER2-targeted ADCs (adjacent MOA, dominant): trastuzumab deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca) — FDA-approved HER2-positive and HER2-low per DESTINY-Breast03/04/06; trastuzumab emtansine (Kadcyla, Roche) — adjuvant/2L HER2-positive. TROP2-targeted ADCs (competing in HR+/HER2-low and TNBC): sacituzumab govitecan (Trodelvy, Gilead) FDA-approved TNBC (~$1.3B 2023 global net sales per Gilead 2023 10-K) and HR+/HER2- metastatic breast; datopotamab deruxtecan (Datroway, AstraZeneca/Daiichi) FDA-approved HR+/HER2- Jan 2025. HER3-targeted ADCs (direct half of Iza-bren's mechanism): patritumab deruxtecan (HER3-DXd, Daiichi) in Phase III HR+/HER2- breast. EGFR-targeted ADCs in breast cancer: limited precedent — Iza-bren's EGFRxHER3 bispecific design is mechanistically differentiated. Other HER2 agents: tucatinib (Tukysa, Pfizer), margetuximab (Margenza, MacroGenics), zanidatamab (Ziihera, Jazz). Anti-PD-L1 in TNBC: atezolizumab (Tecentriq, Roche) — US accelerated approval withdrawn 2021; pembrolizumab (Keytruda, Merck) + chemo in PD-L1+ TNBC. For a commercial lead, Iza-bren must win in HER3+/HER2-low or biomarker-defined TNBC sub-segments to carve franchise value against Enhertu and the TROP2 class.
Iza-bren (BL-B01D1) is a Phase II/III EGFRxHER3 bispecific ADC being developed for EGFR-mutated non-small cell lung cancer (EGFRm NSCLC), a market built around covalent EGFR TKIs. 3rd-generation EGFR TKIs (standard of care): osimertinib (Tagrisso, AstraZeneca) — FDA-approved 1L EGFRm NSCLC per FLAURA/FLAURA2 and adjuvant per ADAURA; ~$5.8B 2023 global revenue (AZ 2023 full-year results). 1st/2nd-gen EGFR TKIs: erlotinib (Tarceva, generic), gefitinib (Iressa, AZ/generic), afatinib (Gilotrif, Boehringer Ingelheim), dacomitinib (Vizimpro, Pfizer). EGFR-exon20 specific: amivantamab (Rybrevant, J&J; EGFRxMET bispecific) — FDA-approved 1L EGFRm NSCLC with chemo (MARIPOSA-2) and EGFR-exon20 (PAPILLON); mobocertinib (Exkivity, Takeda — US withdrawn Oct 2023). HER3-targeted ADCs (direct MOA competitor to Iza-bren HER3 arm): patritumab deruxtecan (HER3-DXd, Daiichi/Merck) — Phase III HERTHENA-Lung02 missed OS in EGFRm NSCLC post-osimertinib (2024). MET-targeted: capmatinib (Tabrecta, Novartis), tepotinib (Tepmetko, Merck KGaA). Anti-PD-1 (different class, limited EGFRm activity): pembrolizumab (Keytruda, Merck) is not preferred in EGFRm. For a commercial lead, Iza-bren's EGFRm NSCLC opportunity is the post-osimertinib resistance setting; HER3-DXd's Phase III OS miss opens space for Iza-bren's bispecific-ADC thesis, with Rybrevant combos the main franchise threat.
Iza-bren (BL-B01D1) is a Phase II/III EGFRxHER3 bispecific ADC (BMS/SystImmune) with reported activity in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC); the NPC landscape is anchored by anti-PD-1 therapy and chemotherapy, with targeted agents emerging. Anti-PD-1 immune checkpoint inhibitors (SOC in R/M NPC 1L/2L): toripalimab (Loqtorzi, Coherus/Junshi) — FDA-approved Oct 2023 for R/M NPC in combination with gemcitabine/cisplatin per JUPITER-02; pembrolizumab (Keytruda, Merck) per KEYNOTE-122 (negative monotherapy vs chemo) — used in practice per KEYNOTE-048 extrapolation; camrelizumab (Airuika, Jiangsu Hengrui; China-approved) in CAPTAIN-1st 1L R/M NPC; tislelizumab (BeiGene; China-approved NPC). Platinum-based chemotherapy (SOC backbone, different class): gemcitabine + cisplatin, 5-FU + cisplatin, paclitaxel + cisplatin regimens. EGFR-targeted agents (adjacent class, limited registrational role): cetuximab (Erbitux, Lilly/Merck KGaA) and nimotuzumab (TheraCIM, Biotech Pharmaceutical) used off-label/regionally. HER3-targeted ADCs (direct MOA adjacent): patritumab deruxtecan (HER3-DXd, Daiichi/Merck) has shown activity in HER3-expressing solid tumors including NPC in early trials. EGFR-targeted ADCs: Iza-bren's bispecific mechanism has no direct EGFR-ADC analogue marketed in NPC. For a commercial lead, Iza-bren's NPC opportunity sits in post-IO/chemo relapse where Loqtorzi's US launch defines the current share leader.
Iza-bren (BL-B01D1) is an EGFRxHER3 bispecific ADC (BMS/SystImmune) in Phase II/III for EGFR-mutated NSCLC after osimertinib progression, a crowded post-TKI setting. 3rd-gen EGFR TKIs (SOC): osimertinib (Tagrisso, AstraZeneca) — FDA-approved 1L, adjuvant, and leptomeningeal EGFRm NSCLC per FLAURA/FLAURA2/ADAURA; 2023 global revenue ~$5.8B (AZ 2023 full-year results). EGFRxMET bispecific: amivantamab (Rybrevant, J&J; with lazertinib per MARIPOSA in 1L and MARIPOSA-2 in post-TKI relapse). 1st/2nd-gen TKIs (generic/legacy): erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif). HER3-targeted ADCs (direct MOA to Iza-bren HER3 arm): patritumab deruxtecan (HER3-DXd, Daiichi/Merck) — HERTHENA-Lung02 Phase III missed OS in EGFRm post-osimertinib (2024). TROP2 ADC in NSCLC: datopotamab deruxtecan (Datroway, AZ/Daiichi) — TROPION-Lung01 was negative overall but showed activity in non-squamous EGFRm subgroup. MET TKIs (bypass resistance): capmatinib (Tabrecta, Novartis), tepotinib (Tepmetko, Merck KGaA). Platinum chemotherapy + pembrolizumab (Keytruda, Merck) — KEYNOTE-789 negative in EGFRm NSCLC, limiting IO role. For a commercial lead, Iza-bren's EGFRm NSCLC franchise threat is gated by Rybrevant+lazertinib's fast ramp and osimertinib-combo trials; HER3-DXd's Phase III failure is a tailwind for Iza-bren's dual-EGFR/HER3 mechanism.
Nasopharyngeal carcinoma (NPC) competitive landscape centers on three MOA tiers relevant to Iza-bren (BL-B01D1), an EGFRxHER3 bispecific ADC. Anti-PD-1 checkpoint inhibitors dominate recurrent/metastatic frontline: toripalimab (Loqtorzi, Coherus/Junshi) received FDA approval October 2023 as the first agent indicated for R/M NPC in combination with gemcitabine-cisplatin based on JUPITER-02; camrelizumab (Airuika, Hengrui) is approved in China; pembrolizumab (Keytruda, Merck, ~$25B 2023 sales) and nivolumab (Opdivo, BMS) are used off-label or in later lines per NCCN. Platinum-doublet chemotherapy (gemcitabine plus cisplatin or 5-FU) remains the chemo backbone per NCCN v2.2024. EGFR-directed mAbs are a smaller segment: cetuximab (Erbitux, Lilly/Merck KGaA) is used in locally advanced NPC in some regions. Emerging ADC and bispecific competitors include trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) in HER2-expressing NPC subsets (early phase) and ivonescimab (PD-1/VEGF bispecific, Summit/Akeso) in broad solid-tumor programs. For BMS, Iza-bren's commercial threat is less from other EGFR/HER3 ADCs (limited direct competition) and more from entrenched anti-PD-1 franchises; first-mover ADC positioning in PD-1-refractory NPC is the key whitespace.
BMS licensed first-in-class EGFRxHER3 bispecific ADC for $800M upfront plus up to $7.6B milestones.
Global Phase I study evaluating safety and efficacy in metastatic NSCLC continues enrollment.
BMS finalized exclusive global license for BL-B01D1. BMS leads ex-China; SystImmune retains China rights.
Encouraging data in urothelial, biliary, and esophageal cancers presented at ESMO.
Early data in urothelial, biliary tract, and esophageal cancers broadened clinical potential beyond NSCLC.
U.S. FDA granted Breakthrough Therapy Designation to izalontamab brengitecan (BL-B01D1) for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions that progressed after an EGFR TKI and platinum-based chemotherapy. Based on BL-B01D1-101, BL-B01D1-203 and BL-B01D1-LUNG-101.
Iza-bren met its dual primary endpoints of progression-free and overall survival at interim analysis of Phase 3 BL-B01D1-307 (NCT06382142) in previously treated unresectable/metastatic triple-negative breast cancer — the first bispecific ADC to report dual positive PFS/OS in TNBC and the third Phase III in which the asset hit its primary endpoint(s).
Too Early to Assess. Assessment of Bristol-Myers Squibb Company's $8.4B acquisition of SystImmune Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / SystImmune Inc. (this deal) | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Oncology deals